Session » RA – Treatment Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2267

A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2253

A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB002, an Anti-TNFα mAb Designed for Extended Half-life, in Healthy Volunteers

10:30AM-12:30PM: Abstract Number: 2254

A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers

10:30AM-12:30PM: Abstract Number: 2269

Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial

10:30AM-12:30PM: Abstract Number: 2281

Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab

10:30AM-12:30PM: Abstract Number: 2275

Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies

10:30AM-12:30PM: Abstract Number: 2286

Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials

10:30AM-12:30PM: Abstract Number: 2283

Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry

10:30AM-12:30PM: Abstract Number: 2257

Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis

10:30AM-12:30PM: Abstract Number: 2282

Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response

10:30AM-12:30PM: Abstract Number: 2256

Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months

10:30AM-12:30PM: Abstract Number: 2280

Development of a Blood-based Cell-free DNA Classifier Assay to Predict Biologic and Targeted Synthetic DMARDs Response in Rheumatoid Arthritis Patients (PRIMA-102)

10:30AM-12:30PM: Abstract Number: 2255

Differences in Pharmacological Prescription to Patients with Recent-onset Arthritis: Analysis from the Gender Perspective

10:30AM-12:30PM: Abstract Number: 2279

Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis Initiating Biologics or Targeted Synthetic DMARDs in Routine Care

10:30AM-12:30PM: Abstract Number: 2259

Effects of Anti-Obesity Medications in RA Patients

10:30AM-12:30PM: Abstract Number: 2274

Efficacy and Safety of the Biased Melanocortin Receptor Agonist AP1189/resomelagon in Combination with Methotrexate in DMARD-naïve Rheumatoid Arthritis Patients: The EXPAND Trial

10:30AM-12:30PM: Abstract Number: 2272

Evolution of Methotrexate and Prednisone Use in the Era of Biologic Therapy: 15-Year Findings from a Large Rheumatoid Arthritis Registry

10:30AM-12:30PM: Abstract Number: 2266

Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2271

Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial

10:30AM-12:30PM: Abstract Number: 2252

Long-term Efficacy of Filgotinib Monotherapy and Combination Therapy: Interim Results from a Post Hoc Analysis of the FINCH 4 Study

10:30AM-12:30PM: Abstract Number: 2270

Low Yield of Routine Serological Screening for Hepatitis B in Patients with Rheumatoid Arthritis Starting Rituximab Therapy in a Non-Endemic Country

10:30AM-12:30PM: Abstract Number: 2265

Patient’s Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study

10:30AM-12:30PM: Abstract Number: 2284

Real-World Evidence of the Antifibrotic Nintedanib in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 74 Patients from Clinical Practice

10:30AM-12:30PM: Abstract Number: 2261

Risk of Cervical Intraepithelial Neoplasia During Janus Kinase (JAK) Inhibitor Treatment in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 2285

Safety and Tolerability of a Combination of Curcumin, Omega-3 and Vitamin-D: Results from the PASCOD Study, an RA Prevention Protocol

10:30AM-12:30PM: Abstract Number: 2278

Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study

10:30AM-12:30PM: Abstract Number: 2260

Statin Use in Patients with Rheumatoid Arthritis (RA) and Osteoarthritis: Are RA Patients More Likely to Receive Statins?

10:30AM-12:30PM: Abstract Number: 2277

Switching to a Targeted Drug with a Different Mode of Action After Discontinuation of the First TNF Inhibitor Is Associated with Better Drug Survival Compared to a Second TNF Inhibitor in Rheumatoid Arthritis: A Propensity Score-matched Analysis from the Czech ATTRA Registry

10:30AM-12:30PM: Abstract Number: 2268

The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data

10:30AM-12:30PM: Abstract Number: 2263

The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies

10:30AM-12:30PM: Abstract Number: 2264

The Risk of Malignancy and Major Adverse Cardiovascular Events with the Use of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Real-World Evidence

10:30AM-12:30PM: Abstract Number: 2258

The Window of Opportunity: A Concept Also Applicable to Undifferentiated Arthritis

10:30AM-12:30PM: Abstract Number: 2273

Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort(CATCH) Study

10:30AM-12:30PM: Abstract Number: 2276

Use of Methotrexate and TNF-α Inhibitors in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease: A Survey of Rheumatologists

10:30AM-12:30PM: Abstract Number: 2262

Window of Opportunity in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease with Abatacept. National Multicenter Study of 526 Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].